Astellas Pharma Gmbh

Juridical Foundation the Chemo-sero-therapeutic Research Institute

The Chemo-sero-therapeutic Research Institute

Fumihiko Sakai

Toshihiro Nakashima

Hirofumi Higuchi

Nobuchika Yamamoto

Masaharu Torikai

Hirotada Fujita

Daisuke Ishikawa

Katsunari Taguchi

Kenji Uehara

The present invention provides a human anti-&#x3b1;9 integrin antibody or an antibody fragment which specifically recognize human &#x3b1;9 integrin and mouse &#x3b1;9 integrin, inhibit interaction with their ligands, particularly, the antibody or antibody fragment which recognize loop regions of human and mouse &#x3b1;9 integrins, a gene encoding the antibody or antibody fragment, a recombinant expression vector containing the gene, a transformant harboring the gene, production method of human anti-&#x3b1;9 integrin antibody or antibody fragment using the transformant, and an agent for the prophylaxis or treatment of rheumatoid arthritis which contains the antibody or antibody fragment.

Human anti-&#x3b1;9 integrin antibody

The present invention provides a humanized anti-human &#x3b1;9 integrin antibody having improved activity and/or property as compared to a donor mouse anti-human &#x3b1;9 integrin antibody, namely, a humanized anti-human &#x3b1;9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:11 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human &#x3b1;9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:13 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human &#x3b1;9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:15 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:9, and a means for the prophylaxis or treatment of various diseases involving human &#x3b1;9 integrin in the pathogenesis, which uses the antibody.

Humanized anti-human &#x3b1;9-integrin antibody

The present invention provides a humanized anti-human osteopontin antibody having better activities (antigen binding activity, leukocyte migration inhibitory activity and the like) and/or stability (resistance to heat, low-pH conditions, denaturants and the like) than those of conventional anti-human osteopontin antibodies.

Humanized anti-human osteopontin antibody

Growing community of inventors

Tokyo, Japan

Fumihiko Sakai